Hannah Fairchild
Family · Ashland, KYNPI 1710529276
Payments from drug & device makers
Across 310 payments — averaging $14.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$967
- Pfizer$518
- Merck$272
- Boehringer Ingelheim$216
- Abbott$203
- plus $878 from 17 others
What the payments were for
- Food & beverage$4,466100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 120 | $1,412 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 60 | $967 |
| Pfizer | 41 | $518 |
| Merck | 17 | $272 |
| Boehringer Ingelheim | 14 | $216 |
| Abbott | 7 | $203 |
| Boston Scientific | 8 | $133 |
| Johnson & Johnson | 9 | $119 |
| E.r. Squibb & Sons, L.L.C. | 6 | $101 |
| Heartflow, Inc. | 2 | $91 |
| Esperion Therapeutics, Inc. | 5 | $85 |
| AstraZeneca | 4 | $70 |
| Novo Nordisk | 3 | $61 |
| Cvrx, Inc. | 4 | $51 |
| Regeneron Healthcare Solutions, Inc. | 2 | $36 |
| Bayer | 1 | $19 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $18 |
| Amgen | 1 | $17 |
| Axonics, Inc. | 1 | $17 |
| United Therapeutics Corporation | 1 | $16 |
| Medtronic | 1 | $15 |
| ZOLL Circulation Inc | 1 | $15 |
| Convatec Inc. | 1 | $13 |
How this compares
$4,466 in reported general payments places this provider in the 90th percentile of 4,374 family providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 237 | $238,990 |
| EntrestoSacubitril/Valsartan | 79 | $74,503 |
| XareltoRivaroxaban | 67 | $70,388 |
| JardianceEmpagliflozin | 16 | $19,124 |
| Repatha SureclickEvolocumab | 14 | $9,851 |
| Ranolazine ErRanolazine | 71 | $9,366 |
| BrilintaTicagrelor | 16 | $7,712 |
| Prasugrel Hcl | 22 | $4,031 |
| Metoprolol Succinate | 261 | $3,182 |
| Flecainide Acetate | 83 | $2,803 |
| Amiodarone Hcl | 92 | $2,338 |
| Atorvastatin Calcium | 262 | $2,114 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 146 | $1,563 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 56 | $1,517 |
| SotalolSotalol Hcl | 67 | $1,504 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $518 | $238,990237 claims |
| NovartisEntresto | $1,412 | $74,50379 claims |
| Johnson & JohnsonXarelto | $119 | $70,38867 claims |
| Boehringer IngelheimJardiance | $216 | $19,12416 claims |
| AstraZenecaBrilinta | $70 | $7,71216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,374 family providers in Kentucky.
Other family in Ashland
- Ashley MaloneAshland$14K
- Bonnie HillLouisa$372K
- Ashley SnellenElizabethtown$190K
- Smita RanjanLouisville$92K
- Elizabeth SaltLexington$89K
- Tracey GaslinLouisville$79K
- Kassandra GreenLouisville$69K
- Danielle RevertLouisville$65K
- Lora BrownMonticellow$61K
- Shelley WaldmanLouisville$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.